Rh Isoimmunization in Pregnancy, Hemolytic Disease of the Fetus and Newborn: Management, Diagnosis, Treatment
Покупка
Новинка
Тематика:
Гинекология. Акушерство
Издательство:
Балтийский федеральный университет им. И. Канта
Составитель:
Пашов Александр Иванович, Никишов Николай Николаевич, Турдиева Алия Сагынбековна, Турдиев Азиз Ширович
Год издания: 2026
Кол-во страниц: 56
Возрастное ограничение: 12+
Дополнительно
Вид издания:
Учебное пособие
Уровень образования:
ВО - Специалитет
ISBN: 978-5-9971-1034-5
Артикул: 891924.01.99
This textbook for the discipline "Obstetrics and Gynecology” complies with the requirements of the Federal State Educational Standard of Higher Education (2020) for specialty 31.05.01 General Medicine. The present textbook covers issues of Rh isoimmunization in pregnancy, as well as hemolytic disease of the fetus and newborn. Includes figures, tables, test questions. It is intended for students in their 4th—6th years of study in specialty 31.05.01 General Medicine.
Тематика:
ББК:
УДК:
ОКСО:
- ВО - Бакалавриат
- 34.03.01: Сестринское дело
- ВО - Специалитет
- 31.05.01: Лечебное дело
- Аспирантура
- 31.06.01: Клиническая медицина
- Ординатура
- 31.08.01: Акушерство и гинекология
ГРНТИ:
Скопировать запись
Фрагмент текстового слоя документа размещен для индексирующих роботов
IMMANUEL KANT BALTIC FEDERAL UNIVERSITY RH ALLOIMMUNIZATION IN PREGNANCY: COMPREHENSIVE STRATEGIES FOR THE DIAGNOSIS AND MANAGEMENT OF HEMOLYTIC DISEASE OF THE FETUS AND NEWBORN Training manual Immanuel Kant Baltic Federal University Press 2026
UDK 616.15-0.53+618.3(075.8)
BBK 57.162.1
R51
Reviewers
Dr M. I. Bazina, Associate Professor,
V. F. Voyno-Yasenetsky Krasnoyarsk State Medical University;
Dr NT. M. Sokolova, Professor, Novosibirsk State Medical University
R51 Rh Isoimmunization in Pregnancy, Hemolytic Disease of
the Fetus and Newborn: Management, Diagnosis, Treatment : training manual / compilers A. I. Pashov, N. N. Nikishov, A. S. Turdieva, A.Sh. Turdiev. — Kaliningrad : Immanuel Kant Baltic Federal University Press, 2026. — 56 p.
ISBN 978-5-9971-1034-5
This textbook for the discipline “Obstetrics and Gynecology” complies with the requirements of the Federal State Educational Standard of
Higher Education (2020) for specialty 31.05.01 General Medicine. The
present textbook covers issues of Rh isoimmunization in pregnancy, as
well as hemolytic disease of the fetus and newborn. Includes figures, tables, test questions.
It is intended for students in their 4th—6th years of study in specialty
31.05.01 General Medicine.
UDK 616.15-0.53+618.3(075.8)
BBK 57.162.1
© Pashov A. I., Nikishov N. N., Turdieva A. S.,
Turdiev A. Sh., compilers, 2026
ISBN 978-5-9971-1034-5 © Design, IKBFU, 2026
ОГЛАВЛЕНИЕ Preface ................................................................................................... Part I. Rhesus (Rh) isoimmunization in pregnancy. hemolytic disease of the fetus ................................................................................ 6 Definition ............................................................................................... 7 Etiology and Pathogenesis ..................................................................... 7 Epidemiology ......................................................................................... 7 Classification.......................................................................................... 11 Diagnosis of Hemolytic Disease of the Fetus ........................................ 12 Clinical Presentation .............................................................................. 13 Physical Examination ............................................................................. 13 Instrumental Diagnostics ........................................................................ 15 Treatment of Hemolytic Disease of the Fetus ........................................ 16 Conservative Treatment .................................................................... 16 Intrauterine Intravascular Transfusion of Packed Red Blood Cells to the Fetus ............................................................................................. 17 Management of Pregnancies with HDF Requiring Intrauterine Transfusion ..................................................................................................... 18 Management of Labor in Rh-Isoimmunized Pregnancies ...................... 19 Prevention of Rh Isoimmunization ........................................................ 20 Non-Specific Prophylaxis ...................................................................... 21 Specific Antenatal Prophylaxis of Rh Isoimmunization ........................ 21 Self-assessment test questions ............................................................... 24 Part II. Hemolytic disease of the newborn. Diagnosis. Treatment ... 28 Definition and Key Links in the Pathogenesis of HDN ......................... 28 Classification of Hemolytic Disease of the Newborn ............................ 29 Complications of HDFN ........................................................................ 33 Diagnosis ............................................................................................... 34 Treatment ............................................................................................... 37
Operative Treatment: Exchange Blood Transfusion (EBT) ................... 42 Prognosis ................................................................................................ 47 Self-assessment test questions ............................................................... 47 Appendices ............................................................................................ 51 List of Abbreviations and Symbols ..................................................... 52 References ............................................................................................. 54
PREFACE Despite significant advances in perinatal medicine, the problem of hemolytic disease of the fetus and newborn in the context of immunoconflict pregnancy cannot be considered completely resolved in our country [2; 3; 14; 15]. Hemolytic disease of the fetus is diagnosed in approximately 0.6 % of newborns in the Russian Federation, and the incidence of Rh isoimmunization has not yet shown a significant downward trend in recent years [14; 15]. Perinatal mortality rates due to hemolytic disease of the fetus remain high, ranging from 15 to 16 ‰ [14; 15; 16]. A significant reduction in perinatal morbidity and mortality from hemolytic disease of the fetus is impossible without organizing measures for the timely and universal prevention of Rh isoimmunization during pregnancy and in the early postpartum period at the population level. Furthermore, advances in molecular genetic technologies have now made it possible to non-invasively determine the fetal Rh genotype in an Rh-negative mother as early as the end of the first trimester of pregnancy through prenatal testing of cell-free fetal DNA in maternal blood samples, with a sensitivity and specificity of 98—100 %. The possibility of non-invasive determination of the fetal Rh genotype in Rh-negative pregnant women allows for a reduction in pregnancy management costs, avoidance of multiple screening tests for Rh antibodies, and ensures the preventive use of anti-Rh immunoprophylaxis only in cases of a Rh-positive fetal genotype. If determining the fetal Rh genotype is not possible, the pregnancy in an Rh-negative woman should be managed as if carrying a Rh-positive fetus [14; 15]. In Rh-isoimmunized women, determining the fetal Rh-D gene avoids unnecessary invasive diagnostic and therapeutic procedures if the fetal blood type is Rh-negative. In cases of a Rh-positive fe
tus, the method allows for early assessment of the risk of developing hemolytic disease of the fetus and timely initiation of diagnostic measures. The use of preimplantation genetic testing in IVF programs when the father has a heterozygous genotype for the Rh factor (RhD+/RhD–) enables families who have experienced fetal or newborn loss due to hemolytic disease to perform selective transfer of embryos with a homozygous Rh-negative genotype into the uterine cavity, thereby preventing the potential development of hemolytic disease in these fetuses. It is important to note that for the healthcare system, the costs associated with implementing the prevention of Rh isoimmunization are significantly lower compared to the costs of treating hemolytic disease of the fetus and newborn [14; 15].